Piramal Pharma Q3 FY25 revenue up 13%
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
The receipt of this permission paves way for the launch of BREZTRI AEROSPHERE in India
Education on Inhalation Therapy & Conducting Nationwide Awareness Camps, Alkem Breathe Initiative Addresses the Alarming Increase in Respiratory Diseases in India
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
Subscribe To Our Newsletter & Stay Updated